316 related articles for article (PubMed ID: 35637432)
1. Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma.
Yang J; Luo G; Li C; Zhao Z; Ju S; Li Q; Chen Z; Ding C; Tong X; Zhao J
BMC Cancer; 2022 May; 22(1):589. PubMed ID: 35637432
[TBL] [Abstract][Full Text] [Related]
2. JAM2 is a prognostic biomarker and inhibits proliferation, metastasis and epithelial-mesenchymal transition in lung adenocarcinoma.
Dong Y; Zhang J; Xie S; Di S; Fan B; Gong T
J Gene Med; 2024 Feb; 26(2):e3679. PubMed ID: 38404047
[TBL] [Abstract][Full Text] [Related]
3. SERPINB5 is a prognostic biomarker and promotes proliferation, metastasis and epithelial-mesenchymal transition (EMT) in lung adenocarcinoma.
He X; Ma Y; Huang Z; Wang G; Wang W; Zhang R; Guo G; Zhang X; Wen Y; Zhang L
Thorac Cancer; 2023 Aug; 14(23):2275-2287. PubMed ID: 37424293
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
[TBL] [Abstract][Full Text] [Related]
5. ZDHHC11B is decreased in lung adenocarcinoma and inhibits tumorigenesis via regulating epithelial-mesenchymal transition.
Dai H; Wu R; Zhang J; Dou R; Xu M; Wang J; Wang J; Su F; Zhang T
Cancer Med; 2023 Aug; 12(16):17212-17222. PubMed ID: 37434393
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of CST1 promotes breast cancer progression and predicts a poor prognosis.
Dai DN; Li Y; Chen B; Du Y; Li SB; Lu SX; Zhao ZP; Zhou AJ; Xue N; Xia TL; Zeng MS; Zhong Q; Wei WD
J Mol Med (Berl); 2017 Aug; 95(8):873-886. PubMed ID: 28523467
[TBL] [Abstract][Full Text] [Related]
7. SPI1-Mediated Upregulation of the
Luo FF; Wang J; Zhang ZF; Lin ST; Huang TJ; Liu BQ; Fan ML; Peng LX; Zheng ST; Yang CF; Huang BJ
Front Biosci (Landmark Ed); 2023 Sep; 28(9):212. PubMed ID: 37796690
[TBL] [Abstract][Full Text] [Related]
8. SPOCK1, as a potential prognostic and therapeutic biomarker for lung adenocarcinoma, is associated with epithelial-mesenchymal transition and immune evasion.
Liu Y; Han T; Wu J; Zhou J; Guo J; Miao R; Xu Z; Xing Y; Bai Y; Hu D
J Transl Med; 2023 Dec; 21(1):909. PubMed ID: 38087364
[TBL] [Abstract][Full Text] [Related]
9. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of Serum CST1 as a Diagnostic Marker for Differentiating Early-Stage Non-Small Cell Lung Cancer from Pulmonary Benign Nodules.
Lai Y; Wang Y; Wu Y; Wu M; Xing S; Xie Y; Chen S; Li X; Zhang A; He Y; Li H; Dai S; Wang J; Lin S; Bai Y; Du H; Liu W
Cancer Control; 2022; 29():10732748221104661. PubMed ID: 35653624
[TBL] [Abstract][Full Text] [Related]
11. RHOV promotes lung adenocarcinoma cell growth and metastasis through JNK/c-Jun pathway.
Zhang D; Jiang Q; Ge X; Shi Y; Ye T; Mi Y; Xie T; Li Q; Ye Q
Int J Biol Sci; 2021; 17(10):2622-2632. PubMed ID: 34326698
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
13. LDH-A promotes malignant behavior via activation of epithelial-to-mesenchymal transition in lung adenocarcinoma.
Hou XM; Yuan SQ; Zhao D; Liu XJ; Wu XA
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30509961
[TBL] [Abstract][Full Text] [Related]
14. Identification of cystatin SN as a novel biomarker for pancreatic cancer.
Jiang J; Liu HL; Liu ZH; Tan SW; Wu B
Tumour Biol; 2015 May; 36(5):3903-10. PubMed ID: 25577248
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
16. Systematic construction and validation of an epithelial-mesenchymal transition risk model to predict prognosis of lung adenocarcinoma.
Tang Y; Jiang Y; Qing C; Wang J; Zeng Z
Aging (Albany NY); 2020 Dec; 13(1):794-812. PubMed ID: 33340396
[TBL] [Abstract][Full Text] [Related]
17. miR-21-5p promotes lung adenocarcinoma cell proliferation, migration and invasion via targeting WWC2.
Wang G; Zhou Y; Chen W; Yang Y; Ye J; Ou H; Wu H
Cancer Biomark; 2020; 28(4):549-559. PubMed ID: 32623387
[TBL] [Abstract][Full Text] [Related]
18. A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma.
Liu XX; Yang YE; Liu X; Zhang MY; Li R; Yin YH; Qu YQ
J Transl Med; 2019 Feb; 17(1):50. PubMed ID: 30777071
[TBL] [Abstract][Full Text] [Related]
19. Actin-like protein 8 promotes cell proliferation, colony-formation, proangiogenesis, migration and invasion in lung adenocarcinoma cells.
Ma S; Wang X; Zhang Z; Liu D
Thorac Cancer; 2020 Mar; 11(3):526-536. PubMed ID: 31962007
[TBL] [Abstract][Full Text] [Related]
20. FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor.
Yu L; Qiao R; Xu J; Han B; Zhong R
Life Sci; 2021 Mar; 268():119022. PubMed ID: 33434533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
